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Abstract 
In Brazil studies with native medicinal plants are usually performed using non-domesticated plants 
and as a result the genetic variability of wild species could express different levels of active princi-
ples changing their therapeutic effect. Based on that, the aim of this study was to demonstrate 
that extract of different half- sib families Cordia verbenacea (DC), widely used as medicinal plant in 
Brazil, have different efficacy in the Total Growth Inhibition (TGI) of 5 different human tumor cell 
lines. Data were statistically analyzed using ANOVA follow by Tuckey test and a heritability estima-
tion of the plant families was performed. The results showed that TGI are different for each plant 
family according with each human tumor cell line. For instance, extracts obtained from families 
3,11 and 12 were more effective to inhibit the U-251 and Ht-29 cell lines compared to the other 
families, while extracts obtained from the family 32 was more effective against thethe PC-3 line. 
The heritability coefficient indicated that plant population selection could promote a genetic 
improvement related to its active principle and their pharmacological effect and could provide the 
identification of the best families according to their pharmacological efficacy.  In conclusion, this 
study suggests that the domestication of a wild medicinal plant should be better monitored by its 
pharmacological effect. 
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Introduction 
In Brazil studies with native medicinal plants are usually performed using non-domesticated 
plants. However, the genetic differences among the wild population make difficult a better inter-
pretation of chemical assays.  Typical genetic variability frequently occurs in wild species that, as a 
result, will express different levels of active principles changing the efficacy of their therapeutic 
effect. Indeed the molecules with pharmaceutical interest are resulted from the secondary metab-
olism of plants that, in turn depends on genetic and ambient factors (Khanna & Shukla, 1991; 
Franz, 1996; Pank, 2006). Once the intrinsic value of a medicinal plant is its therapeutic effect, 
concerning its active principle, pharmacological assays could be used to determine the phenotype 
of an individual or a studied population. Cordia verbenacea DC. Boraginaceae is a medicinal plant 
widely used in Brazil. Their effects are popularly described as anti-inflammatory, anti-arthritic, 
analgesic and antiulcerogenic (Lorenzi and Matos, 2008). Based on that, the aim of this study was 
to demonstrate that extract of different families of the Cordia verbenacea have different efficacy in 
the Total Growth Inhibition (TGI) of 5 different human tumor cell lines.  
Materials and Methods 
Plants extracts samples are obtained from a field experiment involving 12 half-sib families of 
Cordia verbenacea. The experimental design was a complete randomized blocks with four replica-
tions. Each parcel contained 5 plants cultivated in a 100 x 200 cm distance. After 1 year, leaves 
were harvested, separated from their branches and dried in an oven at 40 °C. The dried leaves are 
grinded to prepare a dry extract. The extract was prepared with ethanol (96º GL) in the proportion 
of 1:5 (dried plant: solvent) with mechanical agitation for 1 ½ h (3 x) at room temperature. The 
extracts were then pooled, filtered and evaporated to dryness. 
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Human tumor cell lines used: U251 (glioma), MCF-7 (breast), NCI-H460 (lung, non-small cells), HT-
29 (colon), PC-3 (prostate) were kindly provided by National Cancer Institute (Frederick, MA, USA). 
Cell culture: stock cultures were grown in medium RPMI 1640 (GIBCO) supplemented with 5 % 
fetal bovine serum (FBS, GIBCO) and 10 U/mL penicillin, 10 µg/mL streptomycin at 37 °C in 5 % 
CO2.Antiproliferative assay: cells in 96-well plates (100 µL cells/well) were exposed to SDE (0.25, 
2.5, 25 and 250 µg/mL in DMSO/RPMI) at 37 ºC, 5 % of CO2 in air for 48 h. Doxorubicin (DOXO) was 
used as standard (0.025, 0.25, 2.5 and 25 µg/mL). Final dimethyl sulfoxide (DMSO) concentration 
did not affect cell viability (0.25 %). Before (T0 plate) and after sample addition (T1 plates), cells 
were fixed with 50 % trichloroacetic acid and cell growth determined by spectrophotometric 
quantification (540 nm) of cellular protein content using sulforhodamine B (SRB) assay (MONKS et 
al., 1991; SHOEMAKER, 2006). The TGI (concentration that produces total growth inhibition) was 
determined through non-linear regression analysis using the concentration-response curve for 
each cell line in the software ORIGIN 8.0® (OriginLab Corporation).  
One-way ANOVA was performed to determine if the Total Growth Inhibition (TGI) were significant 
different (p<0.05) among treated groups. If so, the post hoc contrasts using the Tukey test were 
performed to determine the basis of the significant difference. 
Results 
As showed in table 1, different plant families had different magnitude of the TGI on human tumor 
cell lines, such as U251 (glioma), NCl-460 (lung non-small cell), PC-3 (prostate) or HT-29 (colon), but 
not in human tumor cell line MC-7 (breast). The effect analyzed by block was also significant; indi-
cating that the complete randomized block experimental design choice was correct. The coeffi-
cient of variation indicates a good precision of the experiment, except concerning to the human 
tumor line MC-7. The heritability estimates indicates that selection in that population would pro-
mote genetic gains.  
Tab. 1 Different plant families of half-sib familiesof Cordia verbenacea show differences in Total Growth Inhibi-
tion of human tumor cell lines. 
    Mean Square 
Source of 
Variation 
Freedom 
Degree 
U251  
µg/ml 
MC-7   
µg/ml 
NCI-460 
µg/ml 
PC-3  
µg/ml HT-29 µg/ml 
Block 3 526,4** 122,20 9547,4** 1684,4** 9088,8** 
Half-sib Fami-
ly 11 1209,6** 229,16 8662,1** 5930** 9371,7** 
Error 33 60,7 105,90 87,9 104,6 242,9 
Mean   62,4 44,3 114,2 83,3 110 
Cv 
 
12,5 23,20 8,2 12,3 14,2 
h2 
 
0,73 0,36 0,75 0,74 0,73 
The symbol (**) means different (P<0.01; ANOVA) among plant families related to Total Growth Inhibition 
(TGI) of U251 (glioma), MCF-7 (breast), NCI-H460 (lung, non-small cells), HT-29 (colon), PC-3 (prostate) cell 
lines. Cv = coefficient of variation; h2 = heritability estimates  
As shown in table 2, different families could be selected according  to their effect in Total Growth 
Inhibition of the human tumor cell lines U-251, NCI-460, PC-3 e HT-29, but not MC-7 cell line. Plants 
extracts with lower TGI indicates greater concentration of the active principle or greater synergic 
effect. Therefore, as smaller is the mean as bigger is its TGI. Agreeing to these data it is possible to 
select the plant families that are more effective in each human tumor cell line tested. The statistical 
analysis shows (ANOVA follow by Tuckey post hoc test; p<0.05). The families 11, 3, 12 and 16 were 
more effective against U-251, NCI-460, PC-3 and HT-29 cell lines.The family 9 was more effective 
against NCI-460, PC-3 and HT-29 cell lines. The family 26 was more effective against HT-29 cell line. 
The family 32 was more effective against PC-3 cell line 
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Tab. 2 Concentration of plant extract necessary to achieve Total Growth Inhibition of different human tumor 
cell lines. Different letters means statistically differences (Tuckey test; p<0.05). 
U-251 
Half-sib 
family 
21 32 9 24 2 33 10 26 16 12 3 11 
TGI 
mean 
(µg/ml) 
123,3  
a 
87,2 
b 
71,2 
bcd 
68,9 
bcd 
67,6 
bcd 
66,2 
bcde 
58,9 
bcde 
48,4 
cde 
48,1 
de 
46,0 
de 
45,5 
de 
37,9 
e 
              
MCF-
7 
Half-sib 
family 
33 32 9 26 10 24 11 16 3 21 2 12 
TGI 
mean 
(µg/ml) 
67,1 
a 
56,0 
a 
51,4 
a 
51,2 
a 
46,7 
a 
44,7 
a 
41,7 
a 
37,9 
a 
36,3 
a 
31,7 
a 
30,5 
a 
30,3 
a 
              
NCI-
460 
Half-sib 
family 
32 26 33 21 24 16 3 12 11 10 9 2 
TGI 
mean 
(µg/ml) 
177,7 
a 
168,2 
abc 
163,9 
abc 
154,5 
abc 
150,5 
abc 
140,3 
bcd 
110,7 
d 
68,7 
e 
39,3 
e 
39,0 
e 
35,7 
e 
35,6 
e 
              
PC-3 
Half-sib 
family 
21 16 26 33 3 9 10 2 24 32 12 11 
TGI 
mean 
(µg/ml) 
154,6 
a 
140,3 
a 
139,6 
a 
135,4 
a 
54,7 
b 
51,9 
b 
50,5 
b 
49,6 
b 
48,5 
b 
45,5 
b 
44,1 
b 
42,2 
b 
              
HT-29 
 
Half-sib 
family 
2 33 32 21 24 9 16 12 3 11 26 10 
TGI 
mean 
(µg/ml) 
  
212,4 
a 
181,7 
ab 
169,4 
abc 
143,3 
bc 
121,5 
cd 
69,2 
d 
68,7 
d 
65,3 
d 
62,6 
d 
59,4 
d 
56,6 
d 
49,3 
d 
Conclusion 
Take together, the data of this study suggest that the domestication of a wild medicinal plant 
should be initially monitored by its pharmacological effect instead by its chemical composition, 
once it is inconstant and depends on its genetic variability and ambient factors (phenotype)  
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